Published in Fitness and Wellness Business Week, April 25th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genaera.
Report 1: Genaera Corporation (GENR) announced that following a comprehensive review of its development portfolio and external market conditions, the board of directors and management have determined that it is in the best interest of the company to terminate the Evizon (squalamine lactate) clinical development program in wet age-related macular degeneration (AMD) and focus company resources on the development of trodusquemine (MSI-1436) for the treatment of obesity.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness and Wellness Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.